Warning: The NCBI web site requires JavaScript to function. more...
Elevated autoantibody content in rheumatoid arthritis synovia with lymphoid aggregates and the effect of rituximab.
Rosengren S, Wei N, Kalunian KC, Zvaifler NJ, Kavanaugh A, Boyle DL.
Arthritis Res Ther. 2008;10(5):R105. Epub 2008 Sep 1.
Related citations
Synovial fluid levels of anti-cyclic citrullinated peptide antibodies and IgA rheumatoid factor in rheumatoid arthritis, psoriatic arthritis, and osteoarthritis.
Caspi D, Anouk M, Golan I, Paran D, Kaufman I, Wigler I, Levartovsky D, Litinsky I, Elkayam O.
Arthritis Rheum. 2006 Feb 15;55(1):53-6.
Prospective cohort study of effects of infliximab on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis.
Bruns A, Nicaise-Roland P, Hayem G, Palazzo E, Dieudé P, Grootenboer-Mignot S, Chollet-Martin S, Meyer O.
Joint Bone Spine. 2009 May;76(3):248-53. Epub 2009 Feb 8.
Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment.
Teng YK, Levarht EW, Hashemi M, Bajema IM, Toes RE, Huizinga TW, van Laar JM.
Arthritis Rheum. 2007 Dec;56(12):3909-18.
Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis.
De Rycke L, Verhelst X, Kruithof E, Van den Bosch F, Hoffman IE, Veys EM, De Keyser F.
Ann Rheum Dis. 2005 Feb;64(2):299-302. Epub 2004 May 27.
Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis.
Cambridge G, Leandro MJ, Edwards JC, Ehrenstein MR, Salden M, Bodman-Smith M, Webster AD.
Arthritis Rheum. 2003 Aug;48(8):2146-54.
Anti-cyclic citrullinated peptide antibody determination in synovial fluid of psoriatic arthritis.
Spadaro A, Riccieri V, Scrivo R, Alessandri C, Valesini G.
Clin Exp Rheumatol. 2007 Jul-Aug;25(4):599-604.
Impact of treatment with infliximab on anticyclic citrullinated peptide antibody and rheumatoid factor in patients with rheumatoid arthritis.
Ahmed MM, Mubashir E, Wolf RE, Hayat S, Hall V, Shi R, Berney SM.
South Med J. 2006 Nov;99(11):1209-15.
Anti-cyclic citrullinated peptide antibody isotypes in rheumatoid arthritis: association with disease duration, rheumatoid factor production and the presence of shared epitope.
Lakos G, Soós L, Fekete A, Szabó Z, Zeher M, Horváth IF, Dankó K, Kapitány A, Gyetvai A, Szegedi G, Szekanecz Z.
Clin Exp Rheumatol. 2008 Mar-Apr;26(2):253-60.
Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response.
Thurlings RM, Vos K, Wijbrandts CA, Zwinderman AH, Gerlag DM, Tak PP.
Ann Rheum Dis. 2008 Jul;67(7):917-25. Epub 2007 Oct 26.
Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment.
Lal P, Su Z, Holweg CT, Silverman GJ, Schwartzman S, Kelman A, Read S, Spaniolo G, Monroe JG, Behrens TW, Townsend MJ.
Arthritis Rheum. 2011 Dec;63(12):3681-91. doi: 10.1002/art.30596.
[Usefulness of anti-cyclic citrullinate peptide antibody determination in synovial fluid analysis of patients with rheumatoid arthritis].
Spadaro A, Riccieri V, Alessandri C, Scrivo R, Valesini G.
Reumatismo. 2006 Apr-Jun;58(2):116-20. Italian.
Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA.
Agrawal S, Misra R, Aggarwal A.
Clin Rheumatol. 2007 Feb;26(2):201-4. Epub 2006 Mar 30.
Monoclonal IgM, IgG, and IgA human rheumatoid factors produced by synovial tissue-derived, EBV-transformed B cell lines.
Kaplan S, Hyman K, Brooks R, Wakai M, Hashimoto S, Furie R, Chiorazzi N.
Clin Immunol Immunopathol. 1993 Jan;66(1):18-25. Erratum in: Clin Immunol Immunopathol 1993 Jul;68(1):93.
Diagnostic utility of anti-cyclic citrullinated peptide antibodies for very early rheumatoid arthritis.
Matsui T, Shimada K, Ozawa N, Hayakawa H, Hagiwara F, Nakayama H, Sugii S, Ozawa Y, Tohma S.
J Rheumatol. 2006 Dec;33(12):2390-7. Epub 2006 Aug 15.
A monoclonal anti-idiotype specific for human polyclonal IgM rheumatoid factor.
Davidson A, Lopez J, Sun D, Prus D.
J Immunol. 1992 Jun 15;148(12):3873-8.
Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment.
Caramaschi P, Biasi D, Tonolli E, Pieropan S, Martinelli N, Carletto A, Volpe A, Bambara LM.
Rheumatol Int. 2005 Nov;26(1):58-62. Epub 2005 Feb 23.
Immune complexes from rheumatoid arthritis synovial fluid induce FcgammaRIIa dependent and rheumatoid factor correlated production of tumour necrosis factor-alpha by peripheral blood mononuclear cells.
Mathsson L, Lampa J, Mullazehi M, Rönnelid J.
Arthritis Res Ther. 2006;8(3):R64. Epub 2006 Mar 28.
Synovial fluid expression of autoantibodies specific for RAGE relates to less erosive course of rheumatoid arthritis.
Pullerits R, Bokarewa M, Dahlberg L, Tarkowski A.
Rheumatology (Oxford). 2007 Aug;46(8):1367-71. Epub 2007 Jun 14.
The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis.
Chen HA, Lin KC, Chen CH, Liao HT, Wang HP, Chang HN, Tsai CY, Chou CT.
Ann Rheum Dis. 2006 Jan;65(1):35-9. Epub 2005 Jun 23.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on